TITLE

Cardiovascular Toxicities of Performance-Enhancing Substances in Sports

AUTHOR(S)
Dhar, Ritesh; Stout, C. William; Link, Mark S.; Homoud, Munther K.; Weinstock, Jonathan; Estes III, N. A. Mark
PUB. DATE
October 2005
SOURCE
Mayo Clinic Proceedings;Oct2005, Vol. 80 Issue 10, p1307
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Athletes commonly use drugs and dietary supplements to improve athletic performance or to assist with weight loss. Some of these substances are obtainable by prescription or by illegal means; others are marketed as supplements, vitamins, or minerals. Nutritional supplements are protected from Food and Drug Administration regulation by the 1994 US Dietary Supplement Health and Education Act, and manufacturers are not required to demonstrate proof of efficacy or safety. Furthermore, the Food and Drug Administration lacks a regulatory body to evaluate such products for purity. Existing scientific data, which consist of case reports and clinical observations, describe serious cardiovascular adverse effects from use of performance-enhancing substances, Including sudden death. Although mounting evidence led to the recent ban of ephedra (ma huang), other performance-enhancing substances continue to be used frequently at all levels, from elementary school children to professional athletes. Thus, although the potential for cardiovascular injury is great, few appropriately designed studies have been conducted to assess the benefits and risks of using performance-enhancing substances. We performed an exhaustive OVID MEDLINE search to identify all existing scientific data, review articles, case reports, and clinical observations that address this subject, in this review, we examine the current evidence regarding cardiovascular risk for persons using anabolic-androgenic steroids including 2 synthetic substances, tetrahydrogestrinone and androstenedione (andro), stimulants such as ephedra, and nonsteroidal agents such as recombinant human erythropoietin, human growth hormone, creatine, and β-hydroxy-β-methylbutyrate.
ACCESSION #
18541523

 

Related Articles

  • Ergogenic supplement use. Guthrie, Ellen Whipple // Pharmacy Today;Apr2008, Vol. 14 Issue 4, p26 

    The article reports on the issue about the increasing use of performance-enhancing supplements in the U.S. According to the author, the Food and Drug Administration (FDA) is prohibited from removing such supplements in the market unless the agency can prove that the product's agent is causing...

  • FDA targets miracle weight loss claims. Devaney, Tim // Hill;11/4/2014, Vol. 21 Issue 110, p17 

    The article reports that the U.S. Food and Drug Administration (FDA) issues new guidelines for the manufacturers of dietary supplements, in an effort to tamp down on misleading weight loss claims.

  • Dietary Supplement Quality and Safety. Coleman, Ellen // Today's Dietitian;Oct2009, Vol. 11 Issue 10, p9 

    The article reports on the concerns over the quality and safety of dietary supplements in the U.S. The Food and Drug Administration (FDA) alerts consumers that certain weight loss supplements contained active pharmaceutical ingredients, and identifies more than 70 products that may be harmful....

  • The Skinny on Alli. Barr, Naomi // O, The Oprah Magazine;Jul2007, Vol. 8 Issue 7, p122 

    The article offers information on Alli, a weight loss pill that has been approved by the U.S. Food and Drug Administration. The drug, which can be purchased without prescription, prevents the body from digesting about 25 percent of the fat in food. In some studies, people who took the pill while...

  • Ergogenic aids. Eichner, E. Randy // Physician & Sportsmedicine;Apr97, Vol. 25 Issue 4, p70 

    Looks at what ergogenic aids are used by athletes to enhance their physical performance. Anabolic steroids; Human growth hormone; Clenbuterol and other beta2 agonists; Caffeine; Creatine.

  • Diet supplements face weighty questions. Clute, Mitchell // Natural Foods Merchandiser;Jun2008, Vol. 29 Issue 6, p15 

    The article reports on the implications of the petition filed by GlaxoSmithKline with the Food and Drug Administration (FDA) asking the agency to treat dietary supplements' weight loss claims as disease claims for dietary supplements in the U.S. The petition was criticized by supplements...

  • FDA Actions. Elliott, William T. // Travel Medicine Advisor;Jul2009 Pharmacology Watch, p2 

    The article focuses on U.S. Food and Drug Authority (FDA) advisories as of July 2009 on certain drugs. FDA has approved AndroGel 1% and Testim 1% which claimed topical testosterone stamina pending the inclusion of a label warning against secondary exposure on children. Likewise, FDA has approved...

  • Dietary supplements for weight loss. Hume, Anne L. // Pharmacy Today;Jul2009, Vol. 15 Issue 7, p25 

    The article reports on the study which reveals that most Americans are taking dietary supplement to loss weight. It also shows that several consumers believe that the U.S. Food and Drug Administration (FDA) has significant regulatory control over dietary supplements and that the products are...

  • Ischemic Colitis Associated With Use of a Bitter Orange-Containing Dietary Weight-Loss Supplement. Sultan, Shahnaz; Spector, Jeremy; Mitchell, Robert M. // Mayo Clinic Proceedings;Dec2006, Vol. 81 Issue 12, p1630 

    Since the US Food and Drug Administration banned the use of dietary supplements containing ephedra in February 2004, numerous "ephedra-free" weight-loss products have appeared on the market. Many of these supplements contain compounds such as bitter orange that are similar in structure and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics